Assessing clinical benefit response in the treatment of gastric @entity5 with non-measurable lesions: a multicenter phase II trial of @entity1311 for XXXX secondary to advanced/recurrent @entity356 .

@entity1 @entity137 @entity5 @entity1311 @entity448 @entity356
BACKGROUND: @entity1311 has shown promise against advanced @entity356 and associated @entity5 with non-measurable lesions. In order to evaluate the therapeutic effect of @entity1311 against @entity356 , a prospective phase II clinical trial was designed according to our previously proposed criteria represented by the clinical benefit response in @entity356 (CBR-GC) criteria and the five-point method (5PM). METHODS: @entity1 with advanced @entity356 with @entity5 were treated with 1-h intravenous (i.v.) infusions of 80 mg/m   of @entity1311 weekly over a 3-week cycle on days 1, 8, and 15, followed by 1 week of rest. Therapeutic responses were measured according to the CBR-GC criteria and the 5PM. RESULTS: The CBR-GC criteria showed improved ascites volume and functional status in 39.1% of @entity1 . A positive CBR-GC response in abdominal girth was seen in 31.3% of @entity1 , and this was significantly correlated with the 5PM-estimated change in ascites volume (p < 0.001). The median number of treatment cycles was 3 (range 1-12). The most common non-hematological @entity137 was @entity448 , in 22.2% of @entity1 . CONCLUSION: Weekly i.v. @entity1311 is a safe and effective chemotherapeutic regimen based on validated CBR-CG criteria.
